Zika Virus Vaccine Candidate
Zika virus infection
Pre-clinicalActive (Research)
Key Facts
About VaxSyna
VaxSyna is a private, pre-clinical stage biotech developing a novel vaccine platform centered on recombinant immune complexes. Its core technology fuses a human IgG antibody to target antigens, forming higher-order complexes that enhance immunogenicity. The company's early research, evidenced by multiple publications, demonstrates proof-of-concept in animal models for viruses like HSV and Zika. VaxSyna operates in the high-potential but competitive vaccine sector, focusing on creating versatile, potent, and rapidly adaptable vaccine candidates.
View full company profileTherapeutic Areas
Other Zika virus infection Drugs
| Drug | Company | Phase |
|---|---|---|
| Zika Program | Integrated Research Associates | Pre-clinical |
| Zika Virus Program | IRBM | Pre-clinical |